Aytu BioPharma Competitors and Similar CompaniesClear all

Aytu BioPharma's competitors and similar companies include Sharon Bio Medicine, Dabur, Cambrex Karlskoga and Shanghai RAAS.

	Aytu BioPharma Aytu BioPharma is initially concentrating on prostate cancer, male sexual dysfunction and male infertility and will expand into other urological indications through acquisition or licensing of approved, commercialized products and late-stage development assets.	Sharon Bio Medicine Sharon Bio-Medicine is a pharmaceutical company.	Dabur Dabur is a provider of pre-clinical solutions.	Cambrex Karlskoga Cambrex Karlskoga is a company that provides contract development and manufacturing organization (CDMO) services.	Shanghai RAAS Shanghai RAAS Blood Products (上海莱士血液制品股份有限公司) is a company researching, inventing, and developing products for the treatment of blood diseases.
Founding Date	Founding Date N/A	Founding Date 1989	Founding Date 1979	Founding Date 1916	Founding Date 1988
Type	Type Public	Type Private	Type Subsidiary	Type Subsidiary	Type Public
Tags	Tags Healthcare drug development	Tags Healthcare drug development	Tags Healthcare drug development	Tags Manufacturing & Industrial drug development pharma	Tags Healthcare drug development
Locations	Locations Englewood, US HQ	Locations Navi Mumbai, IN HQ Navi Mumbai, IN Navi Mumbai, IN	Locations HQ	Locations Björkborn, SE HQ	Locations CN HQ
Employees	Employees 537% decrease	Employees 3882% increase	Employees 1991% decrease	Employees 203	Employees 3,350
Valuation ($)	Valuation ($) 12.3 m	Valuation ($) N/A	Valuation ($) N/A	Valuation ($) N/A	Valuation ($) 6.8 b
Financial
Revenue (est.)	Revenue (est.) $66.4m (FY, 2025)	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) ¥7.3b (FY, 2025)
Cost of goods	Cost of goods $20.6m (FY, 2025)	Cost of goods N/A	Cost of goods N/A	Cost of goods N/A	Cost of goods ¥4.6b (FY, 2025)
Gross profit	Gross profit $45.8m (FY, 2025)	Gross profit N/A	Gross profit N/A	Gross profit N/A	Gross profit ¥2.7b (FY, 2025)
Net income	Net income ($13.6m) (FY, 2025)	Net income N/A	Net income N/A	Net income N/A	Net income ¥1.6b (FY, 2025)